US 12,109,035 B2
System and method for treating and monitoring post traumatic stress disorder (PTSD)
Carolyn Mountford, East Ryde (AU); David Crompton, Highfields (AU); Nathan Tosh, Mount Lofty (AU); and Rosanna Tremewan, Camp Hill (AU)
Assigned to DatChem, Brisbane (AU)
Filed by Translational Research Institute Pty Ltd as trustee for Translational Research Institute Trust, Woolloongabba (AU)
Filed on Feb. 14, 2020, as Appl. No. 16/791,797.
Claims priority of provisional application 62/806,400, filed on Feb. 15, 2019.
Prior Publication US 2020/0261012 A1, Aug. 20, 2020
Int. Cl. A61B 5/00 (2006.01); A61B 5/05 (2021.01); A61B 5/055 (2006.01); A61B 5/16 (2006.01); A61B 5/374 (2021.01); A61M 21/00 (2006.01); A61N 2/00 (2006.01); A61N 2/02 (2006.01); G01R 33/46 (2006.01); G16H 20/70 (2018.01)
CPC A61B 5/4076 (2013.01) [A61B 5/374 (2021.01); A61N 2/006 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A method of monitoring therapeutic interventions for treating a patient with PTSD by:
using a scanner to obtain pre-treatment neural spectroscopic data of at least one neuromarker chemical in a brain of the patient before treatment, the at least one neuromarker chemical being at least one of Fuc 7, and PE-Histidine, using a comparator to compare the pre-treatment neural spectroscopic data with neural spectroscopic data of a healthy profile, treating the patient with at least one treatment protocol, after the at least one treatment protocol is performed on the patient, using the scanner to obtain post-treatment neural spectroscopic data of the at least one neuromarker chemical in the brain of the patient, and using the comparator to compare the pre-treatment and post-treatment neural spectroscopic data.